🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study is a prospective, open-label, randomized, multicenter, two-cohor...
Status
Recruiting
Location
The Second Affiliated Hospital of Dalian Medical University
Start Date
2025-06-25
Trial ID
NCT07285382
Treatments Being Tested
This study aimed to evaluate the efficacy and safety of Dalpiciclib combine...
Status
Not Yet Recruiting
Location
West China Hospital, Sichuan University
Start Date
2023-12-01
Trial ID
NCT05979220
Treatments Being Tested
In this single arm, open label, phase 2 trial, operable patients with stage...
Status
Unknown
Location
Yantai Yuhuangding Hospital
Start Date
2022-08-04
Trial ID
NCT05800756
Treatments Being Tested
This study is a prospective, open-label, multicenter, randomized controlled...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2025-06-15
Trial ID
NCT07005557
Treatments Being Tested
This is a single-arm, open-label, exploratory clinical study...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2024-10-15
Trial ID
NCT06613373
Treatments Being Tested
to assess the effect of dalpiciclib plus letrozole and capecitabine of firs...
Status
Unknown
Location
Multiple Locations
Start Date
2022-08-10
Trial ID
NCT05469750
Treatments Being Tested
The purpose of this study is to establish a prospective, single-center plat...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Start Date
2022-11-01
Trial ID
NCT05582499
Treatments Being Tested
Neutropenia is a common complication from dalpiciclib. Mecapegfilgramtim (c...
Status
Active Not Recruiting
Location
中山大学中山纪念医院
Start Date
2022-08-01
Trial ID
NCT05463601
Treatments Being Tested
This study is a multicenter, prospective, randomized, open-label clinical s...
Status
Recruiting
Location
Fujian Cancer Hosptial
Start Date
2026-01-21
Trial ID
NCT07581834
CDK4/6 inhibitors are currently the standard treatment for female breast ca...
Status
Unknown
Location
Peking Union Medical College Hospital
Start Date
2023-05-15
Trial ID
NCT05861830